Mei Ri Jing Ji Xin Wen·2025-08-19 15:31Core Viewpoint - Nocera Biopharma (09969.HK) reported a significant revenue increase of 74.26% year-on-year for the first half of 2025, driven by the sales growth of its core product, Obinutuzumab (brand name: Yinuokai), and a licensing agreement with Prolium [1] Financial Performance - The company's revenue for the first half of 2025 reached 731 million yuan, while the net profit attributable to shareholders was a loss of 30.09 million yuan, which represents a narrowing of losses compared to the previous year [1] - Drug revenue increased by 53.5% year-on-year to 640 million yuan, with Obinutuzumab's revenue growing by 52.8% to 637 million yuan [2] Product Development and Approvals - Obinutuzumab has been approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adult patients, marking its first indication as a first-line therapy [2] - The company’s other product, Tanshimab (brand name: Mingnuokai), received approval for use in combination with Lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [2] Commercialization Efforts - Nocera Biopharma increased its sales and distribution expenses by approximately 55% year-on-year to 244 million yuan, primarily due to commercial expansion and share-based payment adjustments [3] - The company has submitted an application for Tanshimab to be included in the commercial insurance innovative drug directory, which has passed preliminary review [3] Strategic Initiatives - The company announced its second business development (BD) transaction in January, partnering with Connoa to license Prolium for the development and commercialization of a bispecific antibody [4] - Nocera Biopharma aims to enhance its global presence and plans to accelerate innovation, commercialization, and internationalization over the next 3-5 years, targeting multiple new drug approvals and international expansions [4] Research and Development - The company’s R&D expenses increased by 6.9% year-on-year to 450 million yuan, reflecting its commitment to advancing clinical projects and building a differentiated research platform [4] - Nocera Biopharma is advancing its BCL2 inhibitor "mesutoclax (ICP-248)" and a new generation TRK inhibitor zurletrectinib (ICP-723), with the latter's new drug application accepted for priority review in China [5][6] Financial Position - As of June 30, 2025, the company held approximately 7.68 billion yuan in cash and cash equivalents, indicating a strong financial position within the biotech sector [6]